EGFR and lung adenocarcinoma: Somatic mutations in the epidermal growth factor receptor (EGFR) gene occur in more than half cases of lung adenocarcinoma in Japan [4] and those are associated with good responsiveness to EGFR tyrosine kinase inhibitors (TKIs), gefitinib and erlotinib [5, 6].